

Supplementary Table S3. Responses by country of employment (Germany vs. other countries).

Treatment	Answers total	Germany (%)	Other Countries (%)	p-value
Respondents	n=139	n=69	n=70	Fisher's exact
Palliative care	16.4 %	19.2	13.8	
Oncological treatment	83.6 %	80.8	86.2	0.1507
Curative intent	44.8 %	42.7	46.6	
Non-curative intent	55.2 %	57.3	53.4	0.5218
Phase I/II trials	88.7 %	87.7	89.5	0.6135
<u>Surgery</u>	43.4 %	39.4	46.8	0.1893
Maximal safe resection	79.9 %	77.0	81.8	
Biopsy	20.1 %	23.0	18.2	0.5355
Molecular workup	95.3 %	95.1	95.5	>0.9999
<u>(Re-) Irradiation</u>	69.5 %	69.0	69.9	0.9062
Local radiotherapy	81.3 %	76.4	85.3	
Craniospinal radiotherapy	18.7 %	23.6	14.7	0.0943
Dose ≤20 Gy	32.3 %	34.9	30.2	
Dose >20 Gy	67.7 %	65.1	69.8	0.4849
<u>Chemotherapy</u>	57.6 %	58.8	56.6	0.7394
Lomustine (CCNU)	17.1 %	12.2	21.4	0.1248
Monotherapy	42.4 %	27.3	10.7	
CCNU + Bevacizumab	24.2 %	9.1	6.8	
CCNU + Temozolomide	24.2 %	45.5	2.9	
Procarbazine + CCNU + VCR	7.8 %	1.1	13.6	0.0009
Temozolomide	19.2 %	21.1	17.5	0.5842
Etoposide + Trofo. oral	7.8 %	15.6	1.0	0.0002
Topo./Eto. +/- Cy oral	7.3 %	8.9	5.8	0.5795
Modified HIT-SKK	5.2 %	8.9	1.9	0.0472
Irinotecan + Bevacizumab	4.1 %	0.0	7.8	0.0076
Vinblastine	3.6 %	5.6	1.9	0.2544
Oral antiangiogenetic comb.	3.6 %	2.2	4.9	0.4521
Other Chemotherapy ^a	18.1 %	16.7	11.7	0.4060
CT plus HDAC inhibitors	12.4 %	21.1	3.9	0.0002
CT plus Chloroquine	2.6 %	5.6	0.0	0.0208
<u>Targeted therapy</u>	89.4 %	88.7	90.0	0.7224
Depending on findings/trials	39.0 %	42.1	36.4	0.3388
BRAF/MEK inhibitor	44.4 %	40.6	47.5	0.2415
BRAF inhibitor	35.9 %	33.3	37.7	
MEK inhibitor	24.4 %	18.5	28.6	
BRAFi + MEKi	39.7 %	44.4	36.4	
Anti EGFR	7.5 %	4.5	10.5	0.0794
TKI (Erlotinib)	45.5 %	40.0	47.1	
Nimotuzumab	31.8 %	20.0	35.3	
EZH2 inhibitor	3.7 %	1.5	5.6	0.1191
CDK inhibitor	2.0 %	1.5	2.5	0.6935
TRK inhibitor	2.0 %	0.8	3.1	0.2276
DRD2 inhibitor (ONC201)	2.0 %	2.3	1.9	>0.9999
mTOR inhibitor	2.0 %	0.8	3.7	0.1333
Other targeted therapy ^b	3.4 %	3.8	3.1	0.7584
Bevacizumab	12.2 %	3.0	19.8	<0.0001
<u>Immunotherapy</u>	43.3 %	48.7	38.8	0.0747
Checkpoint inhibitor	30.3 %	39.7	17.4	0.0051
Nivolumab	48.8 %	48.1	50.0	
plus Entinostat	42.9 %	29.6	12.5	
plus Vaccine	27.9 %	37.0	25.0	
Comb. (Ipilimumab)	14.0 %	0.0	37.5	
Tumor vaccine	16.2 %	26.0	5.8	0.0051
Dendritic cells	52.2 %	52.6	50.0	
Other immunotherapy ^c	4.9 %	4.1	5.8	0.7131
Tumor-Treating Fields	15.9 %	16.0	15.8	0.0999
Intraventricular CT	12.9 %	17.5	9.0	0.0305

Supplementary Table S3. Responses by country of employment (Germany vs. other countries).

Chosen answers and free-text proposals by the respondents from Germany vs. other European countries. Percentage is related to the respective number of answers for each question. Bold font indicates a statistically significant difference.

a "Metronomic chemotherapy" not specified, 2.1%; HIT-HGG-Rez-Immunovac study, 2.1%; LGG chemotherapy (carboplatin, vincristine), 2.1%; vincristine or vinorelbine, 2.1%; PEI (cisplatin, etoposide, ifosfamide), 1.6%; carboplatin + etoposide, 1.6%; High-dose chemotherapy + autologous stem cell transfusion, 1.0%; RIST (rapamycin, irinotecan, dasatinib, temozolomide), 1.0%; ICE (ifosfamide, carboplatin, etoposide), 1.0%; carboplatin-based, 0.5%; eribulin, 0.5%; fotemustine, 0.5%; Metro-PD1, 0.5%; adriamycine, 0.5%; vindesine, 0.5%, VAC (vincristine, actinomycin-d, cyclophosphamide), 0.5%;

b Hedgehog inhibitor, 0.7%; PDGFR inhibitor, 0.3%; PIK3CA inhibitor, 0.3%; PARP inhibitor, 0.3%; ALK inhibitor, 0.3%;

c CAR-T cells, 3.5%; Oncolytic virus, 1.4%;

d BRAFV600E mutation and SMARCB1 deletion;

e EGFR overexpression and CDKN2A deletion;

f KIAA1549-BRAF fusion

Abbreviations: VCR, vincristine; Trofo, trofosfamide; Topo, topotecan; Eto, etoposide; Cy, cyclophosphamide; comb., combination; CT, chemotherapy; TKI, tyrosine kinase inhibitor.